Canopy, the leader in Enterprise AI for oncology, today announced a partnership with Columbus Oncology & Hematology, a leading independent practice in central Ohio and a member of the ONCare Alliance. Columbus Oncology & Hematology is implementing Canopy’s comprehensive platform, including Remote Therapeutic Monitoring (RTM) and operational AI, to support care delivery between visits for both patients and staff.
Canopy helps practices manage the growing complexity of cancer care by providing a unified AI platform across patient services: triage, call center and communications, front office, and pharmacy. By embedding AI and automation into existing workflows, Canopy enables faster issue resolution, reduces manual work, and helps practices capture sustainable reimbursement.
In oral and poster presentations at the 2026 ASCO Annual Meeting, active use of the Canopy RTM platform demonstrated:
These studies add to Canopy’s growing foundation of clinical evidence.
Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.us.
Columbus Oncology & Hematology is a community-based private practice serving people in central Ohio and the surrounding communities across three sites of care. Made up of hematology and medical oncology experts, Columbus Oncology & Hematology delivers high-quality care with compassion and convenience—all so patients can focus on healing while achieving the best possible outcomes. For more information, visit https://www.coainc.net.
Interested in learning more? Contact our team using the button below.
1 Essell JH, Derman BA, Kolodziej MA, et al. Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors. J Clin Oncol. 2026;44(suppl 16):abstr 11005. doi:10.1200/JCO.2026.44.16_suppl.11005
2 Derman BA, Kolodziej MA, Essell JH, et al. Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors. J Clin Oncol. 2026;44(suppl 16):abstr 11108. doi:10.1200/JCO.2026.44.16_suppl.11108